HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Innate nuclear sensor IFI16 translocates into the cytoplasm during the early stage of in vitro human cytomegalovirus infection and is entrapped in the egressing virions during the late stage.

AbstractUNLABELLED:
Intrinsic immune mechanisms mediated by constitutively expressed proteins termed "restriction factors" provide frontline antiviral defense. We recently demonstrated that the DNA sensor IFI16 restricts human cytomegalovirus (HCMV) replication by downregulating viral early and late but not immediate-early mRNAs and their protein expression. We show here that at an early time point during the in vitro infection of low-passage-number human embryonic lung fibroblasts, IFI16 binds to HCMV DNA. However, during a later phase following infection, IFI16 is mislocalized to the cytoplasmic virus assembly complex (AC), where it colocalizes with viral structural proteins. Indeed, upon its binding to pUL97, IFI16 undergoes phosphorylation and relocalizes to the cytoplasm of HCMV-infected cells. ESCRT (endosomal sorting complex required for transport) machinery regulates the translocation of IFI16 into the virus AC by sorting and trafficking IFI16 into multivesicular bodies (MVB), as demonstrated by the interaction of IFI16 with two MVB markers: Vps4 and TGN46. Finally, IFI16 becomes incorporated into the newly assembled virions as demonstrated by Western blotting of purified virions and electron microscopy. Together, these results suggest that HCMV has evolved mechanisms to mislocalize and hijack IFI16, trapping it within mature virions. However, the significance of this IFI16 trapping following nuclear mislocalization remains to be established.
IMPORTANCE:
Intracellular viral DNA sensors and restriction factors are critical components of host defense, which alarm and sensitize immune system against intruding pathogens. We have recently demonstrated that the DNA sensor IFI16 restricts human cytomegalovirus (HCMV) replication by downregulating viral early and late but not immediate-early mRNAs and their protein expression. However, viruses are known to evolve numerous strategies to cope and counteract such restriction factors and neutralize the first line of host defense mechanisms. Our findings describe that during early stages of infection, IFI16 successfully recognizes HCMV DNA. However, in late stages HCMV mislocalizes IFI16 into the cytoplasmic viral assembly complex and finally entraps the protein into mature virions. We clarify here the mechanisms HCMV relies to overcome intracellular viral restriction, which provides new insights about the relevance of DNA sensors during HCMV infection.
AuthorsValentina Dell'Oste, Deborah Gatti, Francesca Gugliesi, Marco De Andrea, Mandar Bawadekar, Irene Lo Cigno, Matteo Biolatti, Marta Vallino, Manfred Marschall, Marisa Gariglio, Santo Landolfo
JournalJournal of virology (J Virol) Vol. 88 Issue 12 Pg. 6970-82 (Jun 2014) ISSN: 1098-5514 [Electronic] United States
PMID24696486 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2014, American Society for Microbiology. All Rights Reserved.
Chemical References
  • Endosomal Sorting Complexes Required for Transport
  • Nuclear Proteins
  • Phosphoproteins
  • Viral Structural Proteins
  • IFI16 protein, human
Topics
  • Cell Nucleus (genetics, metabolism)
  • Cytomegalovirus (genetics, physiology)
  • Cytomegalovirus Infections (genetics, metabolism, virology)
  • Cytoplasm (metabolism, virology)
  • Endosomal Sorting Complexes Required for Transport (metabolism)
  • Host-Pathogen Interactions
  • Humans
  • Nuclear Proteins (genetics, metabolism)
  • Phosphoproteins (genetics, metabolism)
  • Protein Transport
  • Viral Structural Proteins (genetics, metabolism)
  • Virion (genetics, physiology)
  • Virus Release
  • Virus Replication

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: